Novartis Ag (NVS) Equity Income (2009 - 2026)

Novartis Ag has disclosed Equity Income across 18 years of filings, most recently posting -$2.0 million for Q2 2026.

• In Q2 2026, Equity Income rose 33.33% year-over-year to -$2.0 million; the TTM figure through Jun 2026 stood at -$15.0 million (up 66.67% YoY), while the FY2025 annual figure was -$12.0 million, up 68.42% from the prior year.
• Equity Income came in at -$2.0 million for Q2 2026 at Novartis Ag, up from -$3.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$2.0 million in Q1 2022 to a low of -$35.0 million in Q4 2024.
• Average Equity Income over 5 years is -$6.8 million, with a median of -$3.0 million recorded in 2023.
• Year-over-year, Equity Income slumped 1350.0% in 2024 and surged 89.66% in 2025.
• Over 5 years, Equity Income stood at -$8.0 million in 2022, then climbed by 12.5% to -$7.0 million in 2023, then slumped by 400.0% to -$35.0 million in 2024, then soared by 82.86% to -$6.0 million in 2025, then jumped by 66.67% to -$2.0 million in 2026.
• Per Business Quant data, the three most recent Equity Income figures were -$2.0 million in Q2 2026, -$3.0 million in Q1 2026, and -$6.0 million in Q4 2025.